Rubedo gains FDA clearance for senotherapeutic trial

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Company advances candidate targeting senescent cells into US study with potential applications beyond dermatology.

Rubedo Life Sciences has announced that the US Food and Drug Administration has cleared its Investigational New Drug application for RLS-1496, a selective modulator of glutathione peroxidase 4 (GPX4). The company will now move into a Phase 1b/2a trial in patients with actinic keratosis, beginning in the fourth quarter of 2025. This follows the start of a European trial earlier this year, in which RLS-1496 is being tested in plaque psoriasis, atopic dermatitis and photoaged skin, with results expected around the same time.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE